证券代码：002317 专门会议审核意见 广东众生药业股份有限公司 第八届董事会独立董事专门会议 2025 年第四次会议审核意见 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法 律法规及规范性文件的有关规定，广东众生药业股份有限公司（以下简称"公司"） 第八届董事会独立董事专门会议 2025 年第四次会议于 2025 年 6 月 24 日在公司 会议室以通讯方式召开。本次会议应出席独立董事3人，实际出席独立董事3人。 经全体独立董事推举，本次会议由独立董事牟小容女士召集并主持。全体独立董 事本着认真、负责的态度，对公司相关议案及事项进行了审议并发表审核意见如 下： 一、会议以 3 票同意，0 票反对，0 票弃权的表决结果，审议通过了《关于 使用募集资金向控股子公司提供借款实施募投项目暨关联交易的议案》。 独立董事： 牟小容 林瑞超 吴清功 二〇二五年六月二十四日 1 公司独立董事一致认为：本次公司使用募集资金向控股子公司提供借款实施 募投项目暨关联交易的事项符合《上市公司募集资金监管规则》《深圳证券交易 所股票上 ...

Macro Economic Overview - Industrial production remains resilient, with overall industrial activity at a historically high level despite weak construction demand and fluctuating automotive and home appliance sales [3][4]. - Recent data indicates that construction starts are low, with cement shipments at historical lows, while industrial production remains strong, particularly in the chemical sector [3]. - The demand side shows weakness in construction, with lower apparent demand for rebar and building materials compared to historical levels [3]. Agricultural Sector - The poultry market is entering a seasonal downturn, leading to potential short-term pressure on chicken prices. In May, the average price for white feather broilers was 7.41 yuan/kg, with a slight decrease from the previous month [7][8]. - The inventory levels for breeding chickens are relatively high, indicating sufficient supply despite the pressure on prices [7]. - Egg prices are expected to decline further in June due to weak terminal demand and high supply pressure, with the average wholesale price for eggs dropping significantly [8][9]. Semiconductor Industry - The domestic high-end semiconductor packaging leader, Shenghe Jingwei, has entered the guidance acceptance phase for its IPO, focusing on advanced packaging materials [13][14]. - The global semiconductor packaging materials market is projected to grow, with a current domestic localization rate of around 15% for semiconductor materials [15]. - Key materials for advanced packaging are being closely monitored, with several domestic companies positioned to benefit from the localization of these materials [15][16][17]. Chemical Industry - The solid-state battery industry is experiencing accelerated industrialization, supported by favorable policies and advancements in high-performance materials [20][21]. - The demand for solid-state batteries is increasing, with several companies making significant progress in material production and technology [22][23]. - The industry is expected to reach a commercialization inflection point by 2030, with ongoing developments in production capabilities and material costs [21][22]. Consumer Services Sector - The 618 shopping festival showed strong performance in instant retail, with significant growth in sales for tea and coffee brands, indicating a recovery in consumer spending [25][26]. - The beauty and personal care sector also saw stable growth during the 618 period, with major e-commerce platforms reporting substantial sales figures [27]. - The overall consumer services index has underperformed the broader market, highlighting competitive pressures within the sector [28]. Pharmaceutical Industry - Zhongsheng Pharmaceutical is focusing on traditional Chinese medicine while innovating in drug development, with a robust pipeline expected to drive future growth [33][34]. - The company has established a sustainable business model that integrates innovative drugs with traditional Chinese medicine, positioning itself well in the market [34]. - The projected net profits for Zhongsheng Pharmaceutical are expected to grow steadily from 3.08 billion yuan in 2025 to 3.92 billion yuan by 2027 [33][34].

中国·北京 北京市朝阳区建外大街甲 14 号广播大厦 5 层&9 层&10 层&13 层&17 层 电话（Tel）：86-10-65219696 传真（Fax）：86-10-88381869 股东大会法律意见书 北京海润天睿律师事务所 关于广东众生药业股份有限公司 2025 年第二次临时股东大会的法律意见书 股东大会法律意见书 北京海润天睿律师事务所 关于广东众生药业股份有限公司 2025 年第二次临时股东大会的法律意见书 致：广东众生药业股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受广东众生药业股份有限 公司（以下简称"公司"）的委托，指派杨雪律师、王佩琳律师出席公司 2025 年第二次临时股东大会，并依据《中华人民共和国证券法》（以下简称"《证券 法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、《广东众 生药业股份有限公司章程》（以下简称"《公司章程》")及其他相关法律、法 规和规范性文件的规定，就公司本次股东大会的召集、召开程序、出席会议人员 的资格、召集人资格、表决程序、表决结果等有关事宜出具本法律意见书。 4．本法律意见书仅供公司本次会议之目的使用，不得用作任何其他用途。 ...

证券代码：002317 公告编号：2025-063 广东众生药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次临时股东大会以现场投票和网络投票相结合的方式召开。 2、本次临时股东大会不存在否决提案，无涉及变更前次股东大会决议的情 形。 一、会议召开和出席情况 广东众生药业股份有限公司（以下简称"公司"）2025 年第二次临时股东大 会采取现场投票与网络投票相结合的方式召开。 （一）会议召开的时间： 1、现场会议召开时间：2025 年 6 月 23 日下午 2:45 2、网络投票时间： （1）通过深交所交易系统进行网络投票的具体时间为 2025 年 6 月 23 日 9:15～9:25，9:30～11:30 和 13:00～15:00； （2）通过互联网投票系统投票的具体时间为2025年6月23日9:15～15:00。 （二）现场会议召开地点：公司会议室 （三）会议召集人：公司董事会 （四）现场会议主持人：公司副董事长张玉冲女士。公司董事长陈永红先生 因公务未能主持会议，根据《公司章程》 ...

医药生物行业资金流出榜 （原标题：14.41亿元主力资金今日抢筹医药生物板块） 沪指6月23日上涨0.65%，申万所属行业中，今日上涨的有28个，涨幅居前的行业为计算机、国防军工，涨幅分别为2.25%、1.97%。医药生物行业 今日上涨0.89%。跌幅居前的行业为食品饮料、家用电器、钢铁，跌幅分别为0.80%、0.43%、0.11%。 医药生物行业今日上涨0.89%，全天主力资金净流入14.41亿元，该行业所属的个股共475只，今日上涨的有400只，涨停的有6只；下跌的有65只， 跌停的有1只。以资金流向数据进行统计，该行业资金净流入的个股有247只，其中，净流入资金超亿元的有5只，净流入资金居首的是永安药业， 今日净流入资金2.35亿元，紧随其后的是塞力医疗、华海药业，净流入资金分别为1.65亿元、1.25亿元。医药生物行业资金净流出个股中，资金净 流出超3000万元的有9只，净流出资金居前的有众生药业、创新医疗、新诺威，净流出资金分别为1.42亿元、6423.29万元、5901.06万元。（数据 宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量 ...

Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Views - The company, Zhongsheng Pharmaceutical, has a solid foundation in traditional Chinese medicine and is innovating to drive future growth. The company has established a development strategy focusing on traditional Chinese medicine as the base, innovation as the lead, and specialty as the focus. The product pipeline is rich and diverse, covering major therapeutic areas such as cardiovascular, respiratory, ophthalmology, and digestion [4][14] - The company is expected to see steady growth in its traditional Chinese medicine segment and significant potential from its innovative drug pipeline. The projected net profits for 2025-2027 are estimated at 308 million, 345 million, and 392 million yuan, respectively, with corresponding EPS of 0.36, 0.41, and 0.46 yuan [4][6] Summary by Sections Company Overview - Zhongsheng Pharmaceutical was established in 1979 and officially restructured in 2001, becoming a top 100 pharmaceutical company in China. It focuses on drug research, production, and sales, with key products including the Compound Xue Shuan Tong series, Nao Shuan Tong capsules, and Zhongsheng pills [4][14] Business Structure and Strategy - The company has formed a sustainable business structure with innovative drugs as the leading development driver, traditional Chinese medicine as the business foundation, and chemical generic drugs as beneficial support. The core products are expected to maintain steady growth despite short-term challenges from price reductions due to centralized procurement [5][30] Financial Performance and Forecast - The company's revenue for 2023 was 2,611 million yuan, with a projected increase to 2,802 million yuan in 2025, reflecting a year-on-year growth of 13.5%. The net profit is expected to recover from a loss in 2024 to 308 million yuan in 2025, with a net profit margin of 11% [7][30] - The gross margin for 2024 is projected at 56.1%, with a net margin of 11.0%. The company has effectively controlled its expense ratios, which are expected to further decline as the innovative pipeline matures [7][30] Product Pipeline and Innovation - The innovative drug pipeline focuses on major indications, including COVID-19, influenza, weight loss, and MASH. Key products include the globally first peptide-based 3CL inhibitor for COVID-19, which was conditionally approved in March 2023, and an influenza treatment approved in May 2025 [6][14] - The company has a rich product pipeline that covers various diseases and promotes departmental collaboration, enhancing its competitive edge in the market [32][35] Market Position and Competitive Advantage - The company has established a strong market position with its core products, particularly the Compound Xue Shuan Tong series, which has seen a significant increase in market share due to its clinical evidence and academic promotion efforts [36][38] - The sales of the Compound Xue Shuan Tong capsules are expected to stabilize and grow, benefiting from demographic trends and the increasing demand for chronic disease treatments [36][39]

Core Viewpoint - The domestic weight-loss drug development sector is experiencing intensified competition, highlighted by the recent advancements of two major pharmaceutical companies, Changshan Pharmaceutical and Zhongsheng Pharmaceutical, in their GLP-1 innovative drugs [1] Group 1: Changshan Pharmaceutical - Changshan Pharmaceutical announced that its subsidiary received approval from the National Medical Products Administration for clinical trials of Aibennate injection for weight-loss indications [2] - The product has already submitted a marketing application for treating type 2 diabetes, which is currently under professional review [2] - Despite the approval for clinical trials, the company indicated that discussions about commercialization are premature, and no comparative studies with market competitors have been conducted yet [2] Group 2: Zhongsheng Pharmaceutical - In contrast, Zhongsheng Pharmaceutical is advancing more rapidly in the GLP-1 sector, having received FDA approval for clinical trials of RAY1225 injection for overweight or obesity indications in the U.S. [3] - The company is actively seeking international collaborations and has initiated a multi-center Phase II clinical study [3] - However, Zhongsheng Pharmaceutical is facing financial pressures, with a reported revenue of 2.467 billion yuan in 2024, a decrease of 5.48%, and a net loss of 299 million yuan, a decline of 213.63% [3] Group 3: Market Potential - The global market for GLP-1 drugs is projected to exceed $150 billion by 2031, indicating significant growth potential in the diabetes and weight-loss sectors [4] - The weight-loss drug index has risen by 24.16% year-to-date, with Changshan Pharmaceutical and Zhongsheng Pharmaceutical's stock prices increasing by 146.37% and 32.89%, respectively, outpacing the Shanghai Composite Index's growth of 0.24% [4] - Despite the promising market, competition is expected to intensify as companies enter this early-stage sector focused on GLP-1 single-target products [4]

Group 1 - President Xi Jinping emphasized the urgency of a ceasefire in the Middle East, stating that the use of force is not the correct way to resolve international disputes [1] - The Chinese photovoltaic industry is expected to see a significant production cut in Q3, with operating rates projected to decrease by 10%-15% [1] - The Ministry of Commerce announced it will expedite the review of export license applications related to rare earths, aiming to maintain global supply chain stability [1] Group 2 - The China Securities Index will officially launch the China Science and Technology Innovation Semiconductor Index on June 20, 2025, which will include 50 companies from the STAR Market and ChiNext [2] - The Ministry of Commerce highlighted the importance of China-EU economic and trade relations, emphasizing ongoing communication and cooperation [2] Group 3 - Kweichow Moutai announced a cash dividend of 27.673 yuan per share for the 2024 fiscal year, totaling 34.671 billion yuan [3] - Zhongqi New Materials reported that Starry Sky Technology has become its controlling shareholder [3] - Lianchuang Optoelectronics noted strong demand for drone countermeasure equipment in the Middle East [3] Group 4 - Fuhuang Steel Structure announced the termination of its plan to issue shares and pay cash for asset purchases [4] - Shengnuo Bio expects a significant increase in net profit for the first half of the year, projecting a year-on-year growth of 254%-332% [4] Group 5 - Zhongyan Chemical plans to agree to a capital reduction for Zhongyan Alkali Industry, which is expected to constitute a major asset restructuring [5] - Kanda New Materials intends to acquire at least 51% of Zhongke Huamei's shares to expand into the semiconductor integrated circuit field [6] Group 6 - Times Publishing clarified that it does not engage in stablecoin business and has a minimal indirect stake in JD Technology [8] - Sanhua Intelligent Controls confirmed the final price for its H-share issuance at 22.53 HKD per share [9] Group 7 - Taiji Co. announced that Changjiang Industrial Group will become its indirect controlling shareholder, with stock resuming trading on June 20, 2025 [10] - Guosen Securities received approval from the Shenzhen Stock Exchange for its acquisition of 96.08% of Wanhe Securities [10] Group 8 - Zhongsheng Pharmaceutical completed the first participant enrollment for its Phase III clinical trial of the innovative drug RAY1225 for obesity [11] - Yuncong Technology stated that its multi-modal AI technology for live detection can be applied to stablecoin wallet scenarios [12]

Investment Rating - The investment rating for the biopharmaceutical industry is "Positive" (maintained) [2] Core Insights - The GLP-1RA class of drugs, represented by Semaglutide and Tirzepatide, is rapidly expanding, creating a multi-billion dollar market opportunity. By 2031, global sales of GLP-1RA drugs are expected to exceed $150 billion, with significant growth anticipated in the weight loss market post-2025 [6][23] - Major multinational corporations (MNCs) are accelerating their entry into the weight loss and diabetes management market, with frequent high-value business development (BD) transactions. Notable acquisitions include Roche's $3.1 billion purchase of Carmot Therapeutics and Merck's acquisition of Hanmi Pharmaceutical's oral GLP-1 small molecule [25][28] - The development of oral and ultra-long-acting products is expected to enhance patient compliance, with ongoing research into both small molecule and peptide oral drugs. Companies like Eli Lilly and Novo Nordisk are leading in this area, with several domestic firms also showing strong potential for international expansion [30] Summary by Sections 1. MNC Accelerating Layout in Weight Loss and Diabetes Management - GLP-1RA drugs are experiencing rapid growth, with Semaglutide and Tirzepatide leading the market. In 2024, Semaglutide's global sales are projected to be approximately $29.2 billion, a year-on-year increase of about 38%, while Tirzepatide's sales are expected to reach $16.5 billion, growing by approximately 208% [16][17] - The market is currently dominated by Novo Nordisk and Eli Lilly, which together hold nearly 97% market share, indicating a duopoly in the sector [23][24] 2. Enhancing Patient Compliance through Oral and Ultra-Long-Acting Products - The development of oral GLP-1RA drugs is seen as a promising avenue to improve patient adherence, with ongoing research into both small molecule and peptide formulations. Companies like Eli Lilly and Novo Nordisk are at the forefront of this innovation [30] - Ultra-long-acting formulations are also being developed, significantly extending dosing intervals and simplifying treatment regimens, which is expected to further enhance patient compliance [7][30] 3. Multi-Target Drug Development and Combination Therapies - Multi-target weight loss drugs are being developed to overcome the limitations of single-target therapies, aiming to activate or inhibit multiple metabolic receptors for improved efficacy. Key targets include GIPR, GCGR, and AMYR [8][29] - Combination therapies that integrate special targets are anticipated to set new standards in weight loss treatment, focusing on fat reduction while preserving lean body mass [8][29] 4. Investment Recommendations - The report recommends several companies as potential investment opportunities, including Innovent Biologics, East China Pharmaceutical, and Boehringer Ingelheim, which are well-positioned in the weight loss and diabetes management sectors. Beneficiary companies include Heng Rui Medicine, Shijiazhuang Pharmaceutical Group, and others [9]

一、RAY1225 注射液 III 期临床试验 证券代码：002317 公告编号：2025-062 广东众生药业股份有限公司 关于控股子公司一类创新药 RAY1225 注射液用于 肥胖/超重的 III 期临床试验完成首例参与者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）控股子公司广东众生睿创 生物科技有限公司（以下简称"众生睿创"）自主研发的一类创新多肽药物 RAY1225 注射液，于近日完成在肥胖/超重参与者的安全性和有效性的多中心、 随机、双盲、安慰剂对照的 III 期临床试验（REBUILDING-2）的首例参与者入 组和给药。具体情况如下： RAY1225 注射液是众生睿创研发的、具有全球自主知识产权的创新结构多 肽药物，具有 GLP-1 受体和 GIP 受体双重激动活性，得益于优异的药代动力学 特性，具备每两周注射一次的长效药物潜力。 RAY1225 注射液用于肥胖/超重参与者及 2 型糖尿病参与者的 III 期临床试 验已获得组长单位伦理审查批件。具体内容详见公司于 2025 年 2 月 ...